Multimodal imaging in a severe case of hydroxychloroquine toxicity

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 3, 2015, Pages 377-379

  Bhavsar, Kavita V ^a,b,c,d   Mukkamala, Lekha K ^e   Freund, K Bailey ^a,b,c,d  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE; HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; ELECTRORETINOGRAM; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MIDDLE AGED; MULTIMODAL IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ACUITY; VISUAL IMPAIRMENT; ATROPHY; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTRORETINOGRAPHY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PIGMENT EPITHELIUM; RETINAL DISEASES; TREATMENT WITHDRAWAL; VISION DISORDERS;

ANTIRHEUMATIC AGENTS; ATROPHY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULAR EDEMA; MIDDLE AGED; MULTIMODAL IMAGING; RETINAL DISEASES; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; WITHHOLDING TREATMENT;

EID: 84928156212     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150323-14     Document Type: Article

References (11)

1. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology. 2003;110:1321-1326.
2. Semmer AE, Lee MS, Harrison AR, Olsen TW. Hydroxychloroquine retinopathy screening. Br J Ophthalmol. 2008;92:1653-1655.
3. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology: Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.
4. Stelton CR, Connors DB, Walia SS et al. Hydroxychloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol. 2013;32(6):895-898.
5. Kellner S, Weinitz S, Farmand G et al. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98(2):200-206.
6. Mititelu M, Wong BJ, Brenner M et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. AMA Ophthalmol. 2013;131(9):1187-1197.
7. Lyon JS. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;156(2):410.
8. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology. 2002;109:1377-1382.
9. Bae EJ, Kyoung RK, Tsang SH, Park SP, Chang S. Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive optics scanning laser ophthalmoscopy. Korean J Ophthalmol. 2014;28(1):100-107.
10. Marmor MF, Melles RB. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology. 2014;121(6):1257-1262.
11. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132(9):1105-1112.